Authorities in China have granted IASO Biotherapeutics the go-ahead to begin clinical testing of the experimental CAR T-cell therapy equecabtagene autoleucel in people with neuromyelitis optica spectrum disorder (NMOSD), IASO announced. NMOSD is an autoimmune disorder wherein the body’s immune system launches an inflammatory attack that damages parts…
C-CAR168 CAR T-cells
Recent Posts
- Immune cell traps may worsen NMOSD attacks, study finds
- Simple blood test may help guide personalized NMOSD treatment
- Life with NMOSD is a game I never asked to play, but keep winning
- Treatment linked to fewer NMOSD relapses, less steroid use in study
- Navigating NMOSD at the intersection of culture and family